

ARTICLE


DOI: 10.1038/s41467-018-03492-6

OPEN

利用双通道微流控液滴筛选平台产生
对应选择性酶的有效分子进化

Efficient molecular evolution to generate enantioselective enzymes using a dual-channel microfluidic droplet screening platform

Fuqiang Ma¹, Meng Ting Chung², Yuan Yao³, Robert Nidetz², Lap Man Lee², Allen P. Liu^{2,4}, Yan Feng¹, Katsuo Kurabayashi^{2,5} & Guang-Yu Yang¹

Directed evolution has long been a key strategy to generate enzymes with desired properties like high selectivity, but experimental barriers and analytical costs of screening enormous mutant libraries have limited such efforts. Here, we describe an ultrahigh-throughput dual-channel microfluidic droplet screening system that can be used to screen up to $\sim 10^7$ enzyme variants per day. As an example case, we use the system to engineer the enantioselectivity of an esterase to preferentially produce desired enantiomers of profens, an important class of anti-inflammatory drugs. Using two types of screening working modes over the course of five rounds of directed evolution, we identify (from among 5 million mutants) a variant with 700-fold improved enantioselectivity for the desired (*S*)-profens. We thus demonstrate that this screening platform can be used to rapidly generate enzymes with desired enzymatic properties like enantiospecificity, chemospecificity, and regiospecificity. 

¹State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.

²Department of Mechanical Engineering, University of Michigan, Ann Arbor, MI 48109, USA. ³MIIT Key Laboratory of Critical Materials Technology for New Energy Conversion and Storage, School of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin 150001, China. ⁴Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA. ⁵Department of Electrical Engineering and Computer Science, University of Michigan, Ann Arbor, MI 48109, USA. These authors contributed equally: Fuqiang Ma, Meng Ting Chung. Correspondence and requests for materials should be addressed to K.K. (email: katsuo@umich.edu) or to G.-Y.Y. (email: yanggy@sjtu.edu.cn)

T

1-6

7-9

10

11

(D D)

$>10^8$

(10^7)

Archaeoglobus ferox (AFE)

(S)-B

A

700-

(FFD)

(Fi. 1)

10,16

(ii)

(DC-FAD)

(Fi. 1)

(Fi. 2)

24

42 μ

FFD

(5-40)

(Fi. 3)

DC-FAD

(Fi. 1)

FAD

10

(Fi. 1)

DC-FAD

1400

100

3

10,000

(Fi. 4)

20

5

D D

FAD

11

(i)

(Fi. 1)

D D

17

18

"D D"

Results

Screening of enzyme selectivity with the DMDS platform.

(i)

(Fi. 1)

(i)





Fig. 1 DMDS platform for screening enzymatic enantioselectivity. **a** Schematic of DMDS operation. Mutant enzyme-expressing single cells are encapsulated in water-in-oil droplets with two fluorogenic substrates and lysis buffer. After the droplets are incubated for a specified time, those droplets containing the desired mutants are enriched via fluorescence-activated droplet sorting. Optical images of DMDS processes: **b** droplet generation; **c** off-chip incubation; **d** droplet reinjection; **e** fluorescence-activated droplet sorting. **f** To avoid crosstalk of two fluorescence signals, the droplets are excited by two spatially separated lasers, which generates two temporally separated emissions. **g** Sorting different populations in a mutation library with the DMDS platform is achieved via two screening modes: a cooperative mode and biased modes. **h** Three fluorogenic substrate designs and their enzymatic reactions yielding two different fluorescence signals. Scale bars: 100 μm









Fig. 2 Directed evolution of the enantioselectivity of AFEST. **a** Conceptual progression of enzymatic enantioselectivity enhancement by iterative rounds of mutagenesis and use of the DMDS process. **b** Cumulative improvement in the enantioselectivity of AFEST resulting from the various directed evolution steps of the present study





(R)-*p*-
 (S)-
 F90 E9) 4D11 (89 E9), 6A8 (89C/
 90- 72-
 6A8 4D11 700- 560-
 AFE A
 89
 89 E9, *E* = 74). (R)-i 4E12,
 D D
 30
 2
 (Fi. 11).
 5 9
 3, (Fi. 12).
 (S)- (R)-
 Fi. 3, A
 (*rac*-1), 6A8 4D11
 (S)-i 97%. (R)- (R)-
 4E12 (*ee*) ee (R)- 95%.
 6A8 4D11
 (S)-i *rac*-2-5, F 35-88. (R)-
 , 4E12, (R)-i *rac*-12-5
 fi

Structural basis for improved enantioselectivity. A
 6A8, 4D11, 4E12
 89,
 (D)
 (R)-i *p*- (S)-i
 AFE
 (S)-i (R)-i (Fi. 4). D
 89C (Fi. 4), (R)- (R)-
 89 (R)- (S)-
 4D11 89 (Fi. 4) 6A8 (S)-
 4E12 (R)- 6A8 4E12
 3, *rac*-4, *rac*-5. D
 4D11 6A8 *rac*-2, *rac*-
 4D11 6A8 6A8. F

rac-1, F90 6A8
rac-1, 4D11, 6A8
 (S)
 (S) *rac-2-5*.
 Fi. 13.

D D
 EC
 33,34 B
 fl

Discussion

FAD 11
 ifi
 FAD
 400-2000 11,23-31
 FAD
 11,23-26 29-31 23,27,28
 D D
 O D D
 B X
 ifi
 ifi
 (S) AFE
 32

C *afes* -F *afes* - pUC18 D A *afi* C (N⁺ 5).

4-()-1-()-1-() () ()

(, 25), (20 , 1), (20 , 1),



10. ... *Anal. Chem.* **86**, 2526–2533 (2014).

11. A ... *Proc. Natl. Acad. Sci. USA* **107**, 4004–4009 (2010).

12. ... *Ind. Eng. Chem. Res.* **54**, 4011–4020 (2015).

13. A ... & ... *Micromachines* **8**, 128 (2017).

14. ... C. ... & C. ... *Curr. Opin. Biotechnol.* **48**, 196–202 (2017).

15. B ... C. ... F. ... (FAD): ... *Lab Chip* **9**, 1850–1858 (2009).

16. F. ... E. ... *Nat. Chem.* **6**, 791–796 (2014).

17. A ... A. ... *Nat. Methods* **3**, 609–614 (2006).

18. ... E. ... *Am. Chem. Soc.* **132**, 10570–10577 (2010).

19. ... *In. Ed. Engl.* **11**, 460–472 (1972).

20. ... A. ... *Microbiol. Biotechnol.* **38**, 61–66 (1992).

21. ... A. ... B. ... & B. ... E. ... *Sci. USA* **109**, 78–83 (2012).

22. ... *Candida albicans* ... *J. Am. Chem. Soc.* **135**, 1872–1881 (2013).

23. ... *Chem. Boil.* **19**, 1001–1009 (2012).

24. ... A. ... *RNA* **21**, 458–469 (2015).

25. ... C. ... A. D. & D. E. ... *Protein Eng. Des. Sel.* **29**, 355–366 (2016).

26. ... A. C. ... *Nat. Commun.* **7**, 11235 (2016).

27. ... *Lab Chip* **14**, 806–813 (2014).

28. ... *Proc. Natl. Acad. Sci. USA* **112**, E4689–E4696 (2015).

29. ... *Biosens. Bioelectron.* **67**, 379–385 (2015).

30. C. ... *Nat. Commun.* **6**, 10008 (2015).

31. ... D. ... *Chem. Boil.* **21**, 1722–1732 (2014).

32. B ... S. ... *Synlett* **2002**, 0837–0850 (2002).

33. ... & ... *Bioelectron.* **22**, 363–370 (2004).

34. ... F. ... D. ... & ... E. ... *Chem. Commun.* **1**, 34–46 (2009).

35. ... & ... D. ... *Anal. Biochem.* **447**, 146–155 (2014).

36. ... A ... 0–14 ... & ... *Anal. Chem.* **89**, 8437–8444 (2017).

37. ... & F. ... *Appl. Microbiol. Biotechnol.* **100**, 79–90 (2016).

38. ... F. ... & C. ... S. ... (A). *J. Am. Chem. Soc.* **138**, 7040–7047 (2016).

39. ... & ... D. A. ... *Biosens. Bioelectron.* **44**, 6–9 (2013).

40. ... F. ... C. E. ... & ... A. ... *PLoS ONE* **9**, 89785 (2014).

41. D ... *Archaeoglobus fulgidus*. *J. Mol. Biol.* **314**, 507–518 (2001).

42. F. ... 03, ... (... , 2008).

43. ... A. D. 4 ... A. D. 4: ... *Comp. Chem.* **30**, 2785–2791 (2009).

44. C. ... D. A. ... A. ... *J. Comp. Chem.* **26**, 1668–1688 (2005).

45. ... C. ... & ... *J. Chem. Phys.* **79**, 926–935 (1983).

46. ... C. ... & B. ... *J. Chem. Phys.* **23**, 327–341 (1977).

47. ... & ... A. E. ... *J. Comp. Chem.* **13**, 952–962 (1992).

Acknowledgements

21627812, 31670791, 31470788, 1263889), F. ... F. ... D. ... C. ... A. ... F. ... L. ... E. ... D. ... (...) 2 ... 000433). D. ... A. ... C. ...

Author contributions

F. ... C. ... F. ... C. ... C. ... F. ... D. ... F. ... C. ... F. ... D. ... C. ... F. ... F. ...

Additional information

Supplementary Information <https://doi.org/10.1038/s41467-018-03492-6>.

Competing interests:


Reprints and permission

<https://www.nature.com/reprints>

Publisher note:

<https://www.nature.com/publisher-note>

Open Access

 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© A. ... () 2018